Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 9/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.46 |
| ▸ | METTL3 | Q86U44 | 3/20 | 0.46 |
| ▸ | ATG7 | O95352 | 4/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20810837 | 1.00 | ADK (0.47) | ADKCA2PRMT5METTL3ATG7 | |
| SCHEMBL15061823 | 0.88 | ADK (0.42) | ADKCA2PRMT5METTL3MTOR | |
| SCHEMBL29720474 | 0.87 | ADK (0.52) | ADKCA2PRMT5METTL3ATG7 | |
| SCHEMBL18214121 | 0.86 | CA2 (0.47) | ADKCA2PRMT5METTL3ATG7 | |
| SCHEMBL2611628 | 0.86 | CA2 (0.48) | ADKCA2PRMT5METTL3ATG7 | |
| SCHEMBL2611648 | 0.84 | ADK (0.38) | ADKCA2PRMT5METTL3ATG7 | |
| SCHEMBL20810884 | 0.84 | ADK (0.38) | ADKCA2PRMT5METTL3ATG7 | |
| SCHEMBL22327447 | 0.84 | POLB (0.56) | — | |
| SCHEMBL30473748 | 0.84 | POLB (0.56) | — | |
| SCHEMBL7623380 | 0.84 | POLB (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399692-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2020-12-24 | — | — | US | disclosed |
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| US-9388464-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-07-12 | — | — | US | disclosed |
| US-9388464-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-07-12 | — | — | US | disclosed |
| EP-3002289-A1 | MODIFIED NUCLEOTIDES FOR POLYNUCLEOTIDE SEQUENCING | Illumina Cambridge Limited (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20160032378-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20160032378-A1 | MODIFIED NUCLEOTIDES | SOLEXA LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| EP-2607369-B1 | Modified nucleotides for polynucleotide sequencing | ILLUMINA CAMBRIDGE LTD (GB) | 2015-09-23 | — | — | EP | disclosed |
| US-9121060-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9121060-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-8071739-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100292452-A1 | Modified nucleotides | ILLUMINA CAMBRIDGE LTD | 2010-11-18 | — | — | US | disclosed |
| US-7771973-B2 | sequencing reactions where nucleotide or nucleoside molecules modified by reversible covalent attachment of 3'-OH blocking groups thereto, are used where blocked nucleotide or nucleoside molecules are required | ILLUMINA CAMBRIDGE LIMITED (GB) | 2010-08-10 | — | — | US | disclosed |
| US-20090325172-A1 | Modified nucleotides | SOLEXA LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-7541444-B2 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2009-06-02 | — | — | US | disclosed |
| US-20070166705-A1 | Modified nucleotides | ILLUMINA CAMBRIDGE LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292452-A1 | Modified nucleotides | ADAR, NT5C2, NSUN2 | ADK 167/4885CA2 1770/4885PRMT5 1033/4885 |
| US-20160362737-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | ADK 167/4885CA2 1757/4885PRMT5 1019/4885 |
| US-20130197209-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | ADK 167/4885CA2 1770/4885PRMT5 1033/4885 |
| US-20120095201-A1 | MODIFIED NUCLEOTIDES | RNMT, NSUN2, NSUN3 | ADK 123/4885CA2 3829/4885PRMT5 203/4885 |
| US-20200399692-A1 | MODIFIED NUCLEOTIDES | ADAR, NT5C2, NSUN2 | ADK 167/4885CA2 1770/4885PRMT5 1033/4885 |
| US-20070166705-A1 | Modified nucleotides | NT5C2, ADAR, DUT | ADK 171/4885CA2 1778/4885PRMT5 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.